PT  - JOURNAL ARTICLE
AU  - SIMON BINDER
AU  - ANDREW L. LEWIS
AU  - RALF JESENOFSKY
AU  - MICHAEL NEUMAIER
AU  - EVELYN JÄGER
AU  - PHILIPP STRÖBEL
AU  - J.-MATTHIAS LÖHR
AU  - MICHAEL KEESE
TI  - Intraperitoneal Use of Doxorubicin Drug-eluting Beads in Sheep: A Pilot Safety Study
DP  - 2012 Dec 01
TA  - Anticancer Research
PG  - 5167--5174
VI  - 32
IP  - 12
4099  - http://ar.iiarjournals.org/content/32/12/5167.short
4100  - http://ar.iiarjournals.org/content/32/12/5167.full
SO  - Anticancer Res2012 Dec 01; 32
AB  - Background: Intraperitoneal carcinmatosis and intra-abdominal tumour cell dissemination may occur with several tumour entities. At this final stage of the tumour disease, systemic chemotherapy remains only palliative and may be accompanied by severe side-effects. Alternatively, compartment-based therapy by intraperitoneal (i.p.) instillation of doxorubicin drug-eluting beads (dox-DEB) has been proposed. Here we investigated the safety, pharmacokinetics and side-effects of i.p. dox-DEB in a large animal trial. Materials and Methods: Ten black-headed meat-sheep received i.p. polyvinyl-alcohol-encapsulated doxorubicin. The plasma concentration of doxorubicin, blood count and laboratory findings were recorded and histological examination of the organs was performed. Results: After i.p. instillation, elevated serum levels of doxorubicin were obtained. After this initial phase, serum levels remained constant. Upon autopsy, no signs of systemic toxicity were detected. Beads remained within the peritoneal cavity and were not systemically distributed. However, we found significant local toxicity in five sheep, three of which died due to severe peritonitis. Conclusion: Doxorubicin can be successfully targeted to the peritoneal cavity by bead encapsulation. Local toxic effects must be controlled in order to facilitate clinical utility.